Back to All

Julie Browne joins Diaceutics as Chief Operating Officer (EXCO)

15 March, 2022

Diaceutics are pleased to announce that Julie Browne has joined Diaceutics as Chief Operating Officer delivering prodigious leadership and strategy as part of the EXCO (Executive Committee) Team.  

Julie is responsible for driving growth guided by Diaceutics' Corporate Strategy and achieved through year-on-year measurable implementation. Her role involves responsibility for horizon-scanning, anticipating global trends and competitive forces, and she is accountable for the strategic, tactical choices and direction of the global business for market share, growth, and profitability. She leads the high performing cross divisional delivery of Diaceutics products and services in line with the Corporate Strategy.

Commenting on her new role, Julie said,Diaceutics is an outstanding high tech life sciences growth story, and it’s a very proud moment for me to be taking up the position of COO. I am a true believer in the power of people to realise lofty ambitions, and I’ve been really impressed by Diaceutics’ focus on driving towards the optimum people-first culture for such a diversely talented global organisation. I am excited about the opportunity to lead out on a world-class people and culture agenda, one which will empower our people to realise their own and their team ambitions and to set the organisation on the right course for sustainable growth.”

Julie specializes in the delivery of strategy and transformation solutions. She possesses more than 20 years’ experience in delivering consultancy assignments for clients in the private and public sectors across the UK and Ireland. An experienced strategist, Julie has an impressive track record in business development and sales generation and has successfully grown businesses, achieving year on year double-digit growth and best-in-class engagement index scores.

As a strategist my focus will be on embedding Diaceutics’ purpose-led strategy across the business grounded in our compelling strategic narrative of why Diaceutics exists, what it does and how it creates value across its multiple constituencies. This is an exciting time for Diaceutics, differentiated as it is by DXRX, to power up its growth with a focus on data, platform network and its suite of customer-centred products; I am relishing the opportunity to bring the best of both strategy and operations to realise our ambitious growth plans in 2022 and beyond, working in sync with my EXCO colleagues and our high performing cross divisional teams,” said Julie.

Commenting on the new appointment, CEO of Diaceutics, Peter Keeling said, “It’s great to have Julie joining the Diaceutics executive leadership team in the critical role of Chief Operating Officer. Julie brings extensive experience and proven excellence in operational leadership of international companies. I am confident that she will contribute significantly to taking Diaceutics operational performance to the next level as well as driving our mission to get every patient access to the right treatment at the right time.”

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny